Compass Pathways stock took a hit in early June. Lykos Therapeutics just got some extremely bearish news from regulators. Regulators being skeptical about Lykos' medicine could be bad for Compass.

Compass is a market leader in real estate brokerage, showing strong growth and cost control despite a sluggish market. I expect the real estate market to improve as the Federal Reserve is likely to ...

A downtrend has been apparent in Compass Therapeutics, Inc. (CMPX) lately with too much selling pressure. The stock has declined 23.5% over the past four weeks. However, given the fact that it is now ...

When it comes to Compass, the whales are buying the dip. Several dozen institutional investors have taken up positions in the residential brokerage as of the end of the second quarter, according to an ...

Compass Inc (NYSE: COMP) shares are popping on Wednesday after an early dip sparked by dilution concerns amid the company's announcement of a $750 million offering of convertible senior notes due 2031 ...